Independent cancer second opinion for patients in Nigeria
For patients and families in Lagos, Abuja and across Nigeria. Kim reviews pathology and molecular reports, advises which testing is worth paying for, and helps families judge whether treatment abroad is likely to change the plan.
What Kim reviews
- Pathology and tumor profiling (NGS) reports, including FoundationOne, Caris, Tempus and Guardant360
- Signatera and other ctDNA results
- Clinical trials that fit your molecular profile, locally and internationally
- Written questions and evidence your oncologist can act on
Price and scheduling
Every engagement starts with a free 15-minute call. No records or payment needed, and no obligation. The Clarity Report is USD $2,000. Active Case Management: $4,500 / month; Concierge Advisory: $7,500 / month.
Video calls in WAT (UTC+1). Itemized paid receipts are provided for HMO, employer, or private insurance reimbursement claims.
All fees are in US dollars and payable online by card. Calls are scheduled to fit your time zone. Records in languages other than English may require translation before review.
Calls are with Kim Lockheimer, PhD, DFM, Chief Scientific Officer. Prices in local currency: /ng/pricing.
All fees are in US dollars and payable online by card. Calls are scheduled to fit your time zone. Records in languages other than English may require translation before review.
Remote scientific review, without traveling abroad. Kim Lockheimer, PhD, DFM is a clinical scientist, not a physician. Diagnosis, prescriptions and treatment decisions remain with your treating oncologist.
Guides for patients
- FoundationOne report explained
- How to read Signatera test results
- Focused Report Review: one report, one question
Other regions
- Independent cancer report review for UK patients
- Canadian patients
- Australian patients
- New Zealand patients
- Kenya
- Israel
- the Philippines
- Pakistan
- Ghana
- the UAE and the Gulf
- Singapore
- Hong Kong
- Independent cancer NGS report review for patients in India
- Germany, Austria and Switzerland
- Ireland
- South Africa
- the Netherlands and the Nordics
- Latin America
- All international consultations